DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?
Platinum-based chemotherapy is routinely used for the treatment of several cancers. Despite all the advances made in cancer research regarding this therapy and its mechanisms of action, tumor resistance remains a major concern, limiting its effectiveness. DNA methylation-based biomarkers may assist...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/12/2918 |
| _version_ | 1797489209249890304 |
|---|---|
| author | Nuno Tiago Tavares Saulė Gumauskaitė João Lobo Carmen Jerónimo Rui Henrique |
| author_facet | Nuno Tiago Tavares Saulė Gumauskaitė João Lobo Carmen Jerónimo Rui Henrique |
| author_sort | Nuno Tiago Tavares |
| collection | DOAJ |
| description | Platinum-based chemotherapy is routinely used for the treatment of several cancers. Despite all the advances made in cancer research regarding this therapy and its mechanisms of action, tumor resistance remains a major concern, limiting its effectiveness. DNA methylation-based biomarkers may assist in the selection of patients that may benefit (or not) from this type of treatment and provide new targets to circumvent platinum chemoresistance, namely, through demethylating agents. We performed a systematic search of studies on biomarkers that might be predictive of platinum-based chemotherapy resistance, including in vitro and in vivo pre-clinical models and clinical studies using patient samples. DNA methylation biomarkers predictive of response to platinum remain mostly unexplored but seem promising in assisting clinicians in the generation of more personalized follow-up and treatment strategies. Improved methodologies for their detection and quantification, including non-invasively in liquid biopsies, are additional attractive features that can bring these biomarkers into clinical practice, fostering precision medicine. |
| first_indexed | 2024-03-10T00:13:13Z |
| format | Article |
| id | doaj.art-92260f902c7b406f952d5621531ecc52 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T00:13:13Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-92260f902c7b406f952d5621531ecc522023-11-23T15:56:25ZengMDPI AGCancers2072-66942022-06-011412291810.3390/cancers14122918DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?Nuno Tiago Tavares0Saulė Gumauskaitė1João Lobo2Carmen Jerónimo3Rui Henrique4Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto), Porto Comprehensive Cancer Centre (P.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto), Porto Comprehensive Cancer Centre (P.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto), Porto Comprehensive Cancer Centre (P.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto), Porto Comprehensive Cancer Centre (P.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto), Porto Comprehensive Cancer Centre (P.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalPlatinum-based chemotherapy is routinely used for the treatment of several cancers. Despite all the advances made in cancer research regarding this therapy and its mechanisms of action, tumor resistance remains a major concern, limiting its effectiveness. DNA methylation-based biomarkers may assist in the selection of patients that may benefit (or not) from this type of treatment and provide new targets to circumvent platinum chemoresistance, namely, through demethylating agents. We performed a systematic search of studies on biomarkers that might be predictive of platinum-based chemotherapy resistance, including in vitro and in vivo pre-clinical models and clinical studies using patient samples. DNA methylation biomarkers predictive of response to platinum remain mostly unexplored but seem promising in assisting clinicians in the generation of more personalized follow-up and treatment strategies. Improved methodologies for their detection and quantification, including non-invasively in liquid biopsies, are additional attractive features that can bring these biomarkers into clinical practice, fostering precision medicine.https://www.mdpi.com/2072-6694/14/12/2918cancerplatinum-based chemotherapyepigeneticsDNA methylationbiomarker |
| spellingShingle | Nuno Tiago Tavares Saulė Gumauskaitė João Lobo Carmen Jerónimo Rui Henrique DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand? Cancers cancer platinum-based chemotherapy epigenetics DNA methylation biomarker |
| title | DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand? |
| title_full | DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand? |
| title_fullStr | DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand? |
| title_full_unstemmed | DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand? |
| title_short | DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand? |
| title_sort | dna methylation biomarkers for prediction of response to platinum based chemotherapy where do we stand |
| topic | cancer platinum-based chemotherapy epigenetics DNA methylation biomarker |
| url | https://www.mdpi.com/2072-6694/14/12/2918 |
| work_keys_str_mv | AT nunotiagotavares dnamethylationbiomarkersforpredictionofresponsetoplatinumbasedchemotherapywheredowestand AT saulegumauskaite dnamethylationbiomarkersforpredictionofresponsetoplatinumbasedchemotherapywheredowestand AT joaolobo dnamethylationbiomarkersforpredictionofresponsetoplatinumbasedchemotherapywheredowestand AT carmenjeronimo dnamethylationbiomarkersforpredictionofresponsetoplatinumbasedchemotherapywheredowestand AT ruihenrique dnamethylationbiomarkersforpredictionofresponsetoplatinumbasedchemotherapywheredowestand |